Lisa Stevens

Bending the Cost Curve: Understanding the GLP-1 Era | Global Conference 2025

Josh Barro, Michael Ferro, Simon Johnson, Lisa Stevens

A panel of industry leaders and medical experts analyzed GLP-1 drugs as a transformative treatment that significantly improves cardiovascular health and reduces long-term healthcare costs, provided patients adhere to therapy. The discussion highlighted a critical adherence gap where global discontinuation rates reach 50%, contrasting with a UK pilot program that achieved 98% retention through AI-driven telehealth and mandatory screening. While facing challenges like high initial costs, supply chain fraud, and societal stigma, successful employer-led programs are emerging as essential mechanisms to manage access, ensure safety, and align financial incentives for sustained workforce productivity.